baber/WOPTO huggingface dataset:
Patent FI-935111-A0 (FI)
Inventor: WADELL LARS GUSTAF ALBERT
IPC: G01F11/20
Filed: 1993-11-18
Abstract: A machine and process for filling a product (13) volumetrically which comprises introducing the product into a hopper (12), recording the level of the product (13) in the hopper (12) and transmitting the recorded information to a computer (18), conveying an empty chamber (19) to a position beneath the hopper (12), automatically adjusting the volume of the empty chamber (19) and filling the empty chamber (19) with the product (13) conveying the filling chamber (19) away from the hopper (12) and discharging the product (13), recording the weight of the discharged product (13) and transmitting the recorded weight to the computer (18), the automatic adjustment of the volume of the empty chamber (19) being based on the recorded imformation transmitted to the computer (18). <IMAGE>
Patent FI-943124-A0 (FI)
Inventor: SWARUP SHANTI
IPC: C09D133/02
Filed: 1994-06-29
Abstract: An ungelled reaction product is prepared from a carboxylic acid group containing polymeric material and an azetidinol containing material having one azetidinol moiety per molecule. The ungelled reaction product is particularly useful as a grind vehicle for pigment grind compositions.
Patent FI-943817-A0 (FI)
Inventor: KALINDJIAN SARKIS BARRET
IPC: A61K31/428
Filed: 1994-08-19
Abstract: Compounds of formula (I) wherein W is a carbonyl, sulphonyl or sulphinyl group, and X is a carbonyl, sulphonyl or sulphinyl group or -C(O)-CH2- (in which the carbonyl group is bonded to Y), provided that at least one of W and X contains carbonyl, Y is R7-O- or R7-N(R8)- (wherein R7 is H or C1 to C15 hydrocarbyl, up to two carbon atoms of the hydrocarbyl moiety optionally being replaced by a nitrogen, oxygen or sulphur atom provided that Y does not contain a -O-O- group, and R8 is H, C1 to C3 alkyl, carboxymethyl or esterified carboxymethyl), Z is selected from (i) -O-R9, (ii), (iii), (iv), wherein R9-R13, Q, Q', G, T, A, B, a and b are as defined in claim 1; or Z is absent and W is H, R1 is H, methyl, halo, carboxy, esterified carboxy, amidated carboxy, carboxymethyl, esterified carboxymethyl or amidated carboxymethyl, R2 is selected from the groups recited above for R1; R3 and R4 (or each R3 and R4 group, when m or n is 2 or more) are independently selected from halo, amino, nitro, cyano, sulphamoyl, C1 to C3 alkyl, C1 to C3 alkoxy, carboxy, esterified carboxy and amidated carboxy, R5 and R6 are independently selected from H and the groups recited above for R3; m, n = 0 to 4, with provisos as given in claim 1 and pharmaceutically acceptable salts thereof, are ligands at cholecystokinin and/or gastrin receptors.
Patent FI-945126-A0 (FI)
Inventor: WULFF FREDERIK KAREL ALBERT
IPC: B29D23/00
Filed: 1994-10-31
Abstract: A method for jointing at least two plastic elements (1-1,2-1), whereby an edge (18) of a first plastic element (1-1) is at least partially placed in an opening of a second plastic element (2-1), the edge (18) of the first plastic element (1-1) being folded over an edge (3) of the opening of the second plastic element (2-1) under plastic deformation, using pressure means (12), whereby the edge of the first plastic element is pressed against a curved butting face of a pressure body being placed in the second plastic element at the opening thereof, that the edge of the first plastic element along the butting face is pushed radially outward and over the edge of the opening of the second plastic element, that the edges of both plastic elements are pressed together by exerting pressure on both sides of the edges, and that use is made of a sealing ring at least partially between the edges. <IMAGE>
Patent FI-950948-A0 (FI)
Inventor: BENNET C FRANK
IPC: A61P35/04
Filed: 1995-03-01
Abstract: Compositions and methods are provided for the treatment and diagnosis of diseases amenable to treatment through modulation of the synthesis or metabolism of intercellular adhesion molecules. In accordance with preferred embodiments, oligonucleotides are provided which are specifically hybridizable with nucleic acids encoding intercellular adhesion molecule-1, vascular cell adhesion molecule-1, and endothelial leukocyte adhesion molecule-1. The oligonucleotide comprises nucleotide units sufficient in identity and number to effect said specific hybridization. In other preferred embodiments, the oligonucleotides are specifically hybridizable with a transcription initiation site, a translation initiation site, 5'-untranslated sequences, 3'-untranslated sequences, and intervening sequences. Methods of treating animals suffering from disease amenable to therapeutic intervention by modulating cell adhesion proteins with an oligonucleotide specifically hybridizable with RNA or DNA corresponding to one of the foregoing proteins are disclosed. Methods for treatment of diseases responding to modulation cell adhesion molecules are disclosed.
Patent FI-952640-A0 (FI)
Inventor: ERNST EBERHARD
IPC: C08F4/6592
Filed: 1995-05-31
Abstract: The prodn. of a catalyst support (I) comprises: (a) drying hydrophilic, macroporous, disperse Al2O3, SiO2, titanium oxide or zirconium oxide, or mixts. or mixed oxides thereof (II), at 110-800 degrees C; (b) reacting with an aluminoxane (III); and then (c) reacting with polyfunctional organic crosslinkers (IV). Also claimed is a catalyst support (I) based on (II) and (III), crosslinked with (IV). Also claimed are supported metallocene catalysts contg. the reaction prods. of (I) with the reaction prods. of metallocene and activators, pref. aluminoxane. Also claimed is a process for the prodn. of polyolefins by (co)polymerisation of olefins using the above supported metallocene catalysts, pref. in the presence of aluminium alkyl.
Patent FI-953569-A0 (FI)
Inventor: WEISS SAMUEL
IPC: A61K35/12
Filed: 1995-07-26
Abstract: Genetically modified, epidermal growth factor-responsive neural stem cells are disclosed that are capable of differentiating into neurons, astrocytes, and oligodendrocytes in vitro. The stem cells can be proliferated in vitro to result in large numbers of cells for use in transplantation to treat various neurological disorders. The stem cells can be obtained from a human or other animal, cultured in vitro in the presence of a growth factor and genetically modified with desired DNA using techniques known in the art. Alternatively, the precursor cells can be derived from a transgenic animal which has had a desired gene inserted into its genome.
Patent FI-953592-A0 (FI)
Inventor: NESTOR JOHN J
IPC: A61K31/522
Filed: 1995-07-27
Abstract: The L-monovaline ester derived from 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol and its pharmaceutically acceptable salts are disclosed which are of value as antiviral agents with improved absorption.
Patent FI-954663-A0 (FI)
Inventor: TAMWARE AB OY
IPC: B62D65/06
Filed: 1995-09-29
Abstract: A method and an arrangement for mounting a door on a vehicle body. In the method, before the door is mounted, it is fastened with its drive mechanism to a separate mounting rack to be substantially ready for use and it is mounted on the body with the mounting rack by attaching it only by means of the mounting rack. The arragnement comprises a separate mounting rack (4) to which the door leaves, door pillars and the drive mechanism are attached before the door is mounted on the vehicle body.
Patent FI-964340-A0 (FI)
Inventor: VOLKMANN ROBERT A
IPC: A61K31/505
Filed: 1996-10-28
Abstract: PCT No. PCT/IB95/00189 Sec. 371 Date Feb. 19, 1997 Sec. 102(e) Date Feb. 19, 1997 PCT Filed Mar. 20, 1995 PCT Pub. No. WO95/29909 PCT Pub. Date Nov. 9, 1995This invention relates to compounds of formula (IA), (IB), (IC) or (ID), wherein m, X, Z, R2, R3, R4, R5, R6, R14 and the dotted lines are as defined below, their pharmaceutically acceptable salts, pharmaceutical compositions containing them and methods of using them to treat Alzheimer's disease, age-associated memory impairment, Parkinson's disease and other central nervous system disorders. The claimed compounds have the ability to enhance the release of neurotransmitters such as acetylcholine, dopamine and serotonin.    <IMAGE>  (IA)
Patent FI-972404-A0 (FI)
Inventor: BARKER RICHARD JOHN
IPC: H04L29/08
Filed: 1997-06-06
Abstract: PCT No. PCT/GB95/02886 Sec. 371 Date Jun. 9, 1997 Sec. 102(e) Date Jun. 9, 1997 PCT Filed Dec. 8, 1995 PCT Pub. No. WO96/18256 PCT Pub. Date Jun. 13, 1996In a multi-processor environment, a plurality of nodes interconnected by a number of networks each run a number of users processes and messages transferred by the processes are transmitted sequentially from a transmitting node to a receiving node using a different network for each datagram to be transferred.
Patent FI-973528-A0 (FI)
Inventor: LINKOLA JANNE
IPC: H04L9/32
Filed: 1997-08-27
Abstract: A procedure and a data communication system in which a service provider provides to a remote user of a service a set of expendable passwords for use by the user in accessing the service via a telecommunication and/or data network. The user's terminal device is provided with means for automatically transmitting a password at log-on to the service, and a server to which the terminal device sets up a connection includes means for identifying the password and for allowing or denying access to the service on the basis of the supplied password. The terminal device further includes means for storing a set of passwords and for selecting, at log-on to a predetermined service, the correct password from the stored set of passwords for automatic addition of the password to a connection setup signal transmitted from the terminal device to the server.
Patent IL-85576-A0 (IL)
Title: Activated rnase l as a marker for virus infections
IPC: G01N33/53
Filed: 1988-02-29
Abstract: A first line of cellular defense against many viruses, including those causing AIDS, is activation of an intracellular biochemical system termed the 2'-5' oligoadenylate/RNase L pathway. It is well known that this pathway malfunctions in individuals with progressive AIDs-related immune dysfunction, but the mechanism of malfunction remained obscure. An inhibitor substance, released in HIV infected cells or a virus directed inhibitor of biochemical intermediates in the 2'-5'A/RNase L pathway, Which by apparently physically attaching to the terminal product (RNase L) in the biochemical pathway, causes the entire system to malfunction which thus allows HIV to multiply uncontrollably has now been identified. The relative intracellular level of this newly-isolated inhibitor has prognostic significance with respect to the development of full-blown AIDS and eventual death.
Patent IL-87098-A0 (IL)
Title: Large sized underground tank with structural stability provided by the interaction between the metal shell,the static concrete facing and the fitting in the hollow space between these two surfaces
IPC: B65D88/76
Filed: 1988-07-14
Abstract: The large-sized underground storage tank is consisting of a metal shell (1), a static facing in reinforced or unreinforced concrete (2) and filling material (4) packed in the hollow space between the two above mentioned surfaced; this filling is consisting of blown bitumen having plasticity properties which provide a stress resisting interaction between the tank shell and its static facing, thus greatly improving the stability of the overall tank structure; hence the possibility to reduce the design strength parameters and to cut the cost of the final product.
Patent IL-88223-A0 (IL)
Title: Polypeptides,process,nucleotide sequences,expression vectors and host organisms for their production and pharmaceutical compositions comprising them
IPC: C12N15/09
Filed: 1988-10-28
Abstract: Polypeptides corresponding to mature human serum albumin residues 1 to n, where n is between 369 and 419 inclusive, are useful as substitutes for albumin in the treatment of burns and shock in humans, the clearances of undesirable compounds, (such as bilirubin) from human blood, in laboratory growth media and in HSA assays. HSA (1-389) is particularly preferred, although not novel per se. The polypeptides may be produced by recombinant DNA techniques, especially in yeast.
Patent IL-92174-A0 (IL)
Title: Nitromethylene compounds,their preparation and their use as pesticides
IPC: A01P7/04
Filed: 1989-10-31
Abstract: The invention provides nitromethylene compounds of general formula   <CHEM> wherein n is 2, 3 or 4, R<1> is an optionally substituted 3-pyridyl group, each R<2> is independently selected from an alkyl group, a haloalkyl group or a hydrogen atom, and R<3> is a hydrogen atom or an alkylcarbonyl group, processes for their preparation, and their use as pesticides, particularly insecticides.
Patent IL-92924-A0 (IL)
Title: Superficial therapeutic system comprising an antineoplastic active substance
IPC: A61K9/70
Filed: 1989-12-29
Abstract: The invention relates to a surface treatment system consisting of an impermeable backing layer, of an agent-containing matrix and of a protective layer which can be detached again, where the matrix contains:
 a. an antineoplastic agent
 b. a self-adhesive polyacrylate
 c. a water absorber
 and where appropriate
 d. a non-adhesive hydrophilic polyacrylate
 e. an emollient and/or penetration promoter.
Patent IL-97376-A0 (IL)
Title: Method for purifying somatotropin monomers
IPC: C12N15/09
Filed: 1991-02-27
Abstract: A method for purifying and recovering biologically active somatotropin monomers from refold solution following the solubilization and naturation of refractile bodies of host cells produced by recombinant DNA methodology. The purification process is based on the discovery that somatotropin monomers and somatotropin oligomers having overlapping isoelectric points may nevertheless be separated by selective precipitation over a narrow pH range. Host cell residues including proteins, pyrogens and other impurities present in the refold solution are effectively removed in the process. The purified somatotropin monomers recovered from solution after removing precipitated solids are suitable for parenteral application to target animals without further purification.
Patent IL-107590-A0 (IL)
Title: Biodegradable compositions comprising starch
IPC: C08L29/02
Filed: 1993-11-12
Abstract: There is provided a biodegradable composition as obtained from a melt comprising converted starch, a plasticizer and at least one member selected from alkenol homopolymers and/or alkenol copolymers which are combined under conditions sufficient to ensure uniform melt formation, in which the at least one member is present in the composition at a concentration of from 10 to 200 parts per 100 parts of dry converted starch. The invention further relates to methods of making the composition, and to articles made from said composition.
Patent IL-110309-A0 (IL)
Title: A method of protecting against neuron loss
IPC: A61P25/28
Filed: 1994-07-13
Abstract: The present invention pertains to a method of protecting against neuron loss in a subject by administering a compound that protects against neuron loss by acting through a vitamin D receptor. Some of these compounds may prevent or retard neuron loss by regulating intraneuronal and/or peripheral calcium and phosphate levels. Other compounds of the invention act through a vitamin D receptor to protect against neuron loss through mechanisms not involving calcium or phosphate regulation. A preferred compound is a biologically active form of vitamin D, a precursor, metabolite, or analog of vitamin D. A preferred form of vitamin D is calcitriol. In another embodiment, the compound is a compound that acts by modulating the biological activity of vitamin D, a precursor, metabolite, or analog of vitamin D. For example, the compound may modulate the biological activity of the vitamin D compound by regulating the amount of the vitamin D compound which is available to protect against neuron loss or it may act by altering the ability of the vitamin D compound to protect against neuron loss. In an alternative embodiment, the compound is a compound that protects against neuron loss through a mechanism similar to that of the vitamin D compound but not involving a vitamin D receptor. The compound is administered to a subject in an amount and over a period of time effective to protect against neuron loss.
Patent IL-131128-A0 (IL)
Title: Nimesulide gel systems for topical use
IPC: A61K9/00
Filed: 1998-02-20
Abstract: The present invention relates to nimesulide topical formulations comprising a carboxyvinylpolymer neutralized as a gel-forming agent or a polyacrylamide-isoparaffin and a solvent selected from the group consisting of ethanol, isopropanol and diethylene glycol monoethyl ether, and to the process for the preparation thereof. Said formulations have advantages such as higher stability of the system and bioavailability of the active ingredient.
Patent IL-142264-A0 (IL)
Title: Device and process to attach a priming system to the body of a grenade
IPC: F42C19/02
Filed: 2000-10-10
Abstract: A system for attaching a priming system onto the body of a grenade, including a support integrally fastened to the grenade body and incorporating a thin cylindrical wall whose upper edge is crimped onto the priming system.
Patent IL-146300-A0 (IL)
Title: Anti-corrosion solutions for air dehumidification systems
IPC: C23F11/18
Filed: 2000-04-13
Abstract: Anti-corrosion solutions useful for air dehumidification processes are disclosed. Phosphonate corrosion inhibiting agents or mixtures thereof can be added to halide solutions of alkali metals, alkaline earth metals, or mixtures thereof, to minimize corrosion of the dehumidifier system.
Patent IL-149184-A0 (IL)
Title: Melanoma vaccine and methods of making and using same
IPC: A61K38/45
Filed: 2000-10-18
Abstract: An immunotherapeutic vaccine providing antigen presenting cells that have be en pulsed with a disrupted cell preparation which includes enucleated cytosol a nd cell membranes of cancer cells infected with a recombinant vaccinia virus encoding at least one immunostimulating molecule. In a preferred embodiment,  the vaccine includes autologous dendritic/monocytic cells (DC/M) that presen t a mixture of antigens (present in the enucleated cytosol and cell membranes)  from melanoma cell lines that have been infected with a recombinant vaccinia  virus encoding IL-2. In another of the preferred embodiments, the enucleated  cytosol and cell membranes are from melanoma cells harvested from the patien t to be treated. A method of making the vaccine and methods of using the vacci ne to stimulate an anti-cancer immune response and to treat a patient with a cancer are also described.
Patent IL-156811-A0 (IL)
Title: Bisaryl derivatives and pharmaceutical compositions containing the same
IPC: A61K31/55
Filed: 2002-01-18
Abstract: The invention relates to a bisaryl derivative of the formula I, wherein (R, R) is selected from (H, H), O, (H, CH3), (H, OH) and (H, CN); Ar is substituted phenyl; and A is a group of following formula II, III, IV or V: The compounds of the invention have FSH receptor modulatory activity and can be used for the control of fertility, for contraception or for treatment of hormone-dependent disorders.
Patent IL-156877-A0 (IL)
Title: Ski exercising and rehabilitation apparatus
Inventor: ANDRZEJ STAFIEJ
IPC: A63B22/02
Filed: 2002-01-31
Abstract: The object of this invention is an the apparatus for ski exercising and rehabilitation, intended to serve for both beginning and professional skiers who shall later ski on snow on either carving or traditional skis, water skis or snowboards. The apparatus according to the invention has upper drive roll ( 11 ) and, below, lower drive roll ( 13 ) and rotatable glide rolls ( 12 ) in between them, all arranged on arc (b) in slanted side beams ( 4 ), ( 5 ) of frame (a), said arc being formed by contact points of the inner side of endless downhill run strip ( 14 ) in form of mat, with 2.4 cm high stiff-and-springing bristle, with rotatable glide rolls ( 12 ), lower drive roll ( 13 ) and upper drive roll ( 11 ), whereas contact point (A) of said endless downhill run strip ( 14 ) and said upper drive roll ( 11 ) is in its highest point, whereas straight line (c) joining contact point (A) and contact point (B) of said endless downhill run strip ( 14 ) with said lower drive roll ( 13 ) and line (f) perpendicular to (c) through point (D) as the outermost point on said arc (b), create distance (d) of 2 cm to 5 cm.
Patent IL-161249-A0 (IL)
Title: Device for accommodating substrates
IPC: H01L21/306
Filed: 2003-03-31
Abstract: The present invention is directed to a device for retaining substrates (S), such as wafers or silicon substrates for the production of photovoltaic elements. The device includes opposing walls ( 1 ) that are interconnected by at least two rod-like carrier elements ( 2, 3 ) that are provided with a retaining means ( 5 ) for retaining the substrates (S) in a vertical position oriented parallel to the walls ( 1 ). At least one rod-like counter carrier element ( 4 ) is also provided and interconnects the two walls ( 1 ). The counter carrier element ( 4 ) is positioned in relation to the carrier elements ( 2, 3 ) so that vertical movement of the substrates (S) relative to the walls ( 1 ) is limited and loading or unloading of the substrates (S) is possible at a slant in relation to the vertical direction (V).
Patent IL-177219-A0 (IL)
Title: Medicinal acidic cannabinoids
IPC: A61K36/185
Filed: 2006-08-01
Abstract: The invention relates to an acidic cannabinoid for medical use and to a cannabis extract comprising an acidic cannabinoid. The extract may comprise one or more compounds selected from the group consisting of cannabidiolic acid (CBD-A), cannabidiol (CBD), cannabigerolic acid (CBGA), cannabigerol (CBG), cannabinolic acid (CBN-A) and cannabinol. <??>The invention further relates to a method for preparing a preparation comprising extracting an acidic cannabinoid from cannabis.
Patent IL-188164-A0 (IL)
Title: Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof
Filed: 2007-12-16
Abstract: The present invention relates to a pharmaceutical formulation for oral administration of the poorly soluble and therefore hardly bioavailable microtubule polymerization inhibitor Indibulin and a process for its manufacture. In particular, there is provided a pharmaceutical formulation of Indibulin for oral administration comprising a granulate containing micronized Indibulin having a particle size of less than 20 mum for at least 99% of the volume of particles, at least one hydrophilic surfactant, and at least one capsulation excipient. The present invention also discloses a method of treating hyperproliferative disorders, malignancies and neoplasms with Indibulin.
Patent IL-192068-A0 (IL)
Title: Container with lid for packaging pourable products
Filed: 2008-06-11
Abstract: A container having a hull which has a primary opening which is closed by a first cover element, in which the top of the container/can comprises a cover tongue (30) formed via a partitioning line (27), which is released after breaking out an opening. The cover tongue (30) has a recessed bead (32) and an adjacent raised bead (36), in which the oblique surface is comprised of at least one section of a side-piece (33) of the recessed piece, and at least one section of the side-piece (37) of the raised bead : Independent claims are included for the following: (1) (A) A container top or cover as a drinking can (2) (B) A method for opening a can or container.